Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.3B | $147M | $48M | $42M | 16.9% | 27.4% | 1897.7% |
| 2024 | $1.0B | $69M | $2M | $46M | 0.9% | 4.1% | -92.6% |
| 2023 | $978M | $106M | $33M | $-38M | 11.5% | 3.8% | -33.7% |
| 2022 | $942M | $117M | $49M | $-5M | 18.7% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 942.26 | 977.89 | 1,017.68 | 1,296.21 |
| Cost Of Revenue | 656.86 | 679.65 | 704.59 | 896.27 |
| Gross Profit | 285.40 | 298.24 | 313.09 | 399.94 |
| Operating Expense | 206.41 | 226.39 | 259.78 | 289.48 |
| Operating Income | 78.99 | 71.85 | 53.32 | 110.46 |
| EBITDA | 117.13 | 106.03 | 69.06 | 146.85 |
| EBIT | 84.43 | 72.02 | 32.89 | 101.24 |
| Pretax Income | 72.33 | 54.07 | 10.92 | 67.99 |
| Tax Provision | 23.15 | 21.46 | 8.50 | 19.73 |
| Net Income | 49.18 | 32.61 | 2.42 | 48.26 |
| Net Income Common Stockholders | 49.18 | 32.61 | 2.42 | 48.26 |
| Total Expenses | 863.28 | 906.04 | 964.36 | 1,185.75 |
| Interest Expense | 12.10 | 17.95 | 21.97 | 33.25 |
| Interest Income | 0.82 | 3.36 | 4.47 | 2.62 |
| Selling General And Administration | 206.41 | 226.39 | 259.78 | 289.48 |
| Normalized EBITDA | 111.92 | 108.49 | 92.93 | 154.72 |
| Normalized Income | 45.63 | 34.09 | 21.27 | 53.85 |
| Market Cap | 2,235.90 | 2,235.90 | 2,235.90 | 2,235.90 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Phibro Animal Health Corporationthis co. | PAHC | $2.2B | 46.33β premium | 7.83 | 16.9% | 19.95 |
| ICU Medical, Inc. | ICUI | $3.0B | 4261.68 | 1.47 | 0.0% | 13.89 |
| Integer Holdings Corporation | ITGR | $3.0B | 28.79 | 1.69 | 5.9% | 14.55 |
| Organon & Co. | OGN | $2.9B | 15.67 | 3.90 | 24.9% | 8.53 |
| Prestige Consumer Healthcare Inc. | PBH |
| $2.9B |
| 13.00 |
| 1.52 |
| 11.7% |
| 10.32 |
| Privia Health Group, Inc. | PRVA | $2.9B | 130.67 | 4.06 | 3.1% | 57.20 |
| Veracyte, Inc. | VCYT | $2.7B | 41.28 | 2.09 | 5.1% | 26.96 |
| National HealthCare Corporation | NHC | $2.7B | 22.47 | 2.52 | 11.2% | 12.59 |
| LeMaitre Vascular, Inc. | LMAT | $2.6B | 44.90 | 6.59 | 14.7% | 30.28 |
| Peer Median | - | 35.04 | 2.31 | 8.6% | 14.22 | |